129 related articles for article (PubMed ID: 24371770)
21. Rapid progression to AML in a patient with germline
McReynolds LJ; Zhang Y; Yang Y; Tang J; Mulé M; Hsu AP; Townsley DM; West RR; Zhu J; Hickstein DD; Holland SM; Calvo KR; Hourigan CS
Leuk Res Rep; 2019; 12():100176. PubMed ID: 31245276
[TBL] [Abstract][Full Text] [Related]
22. GATA2 deficiency and related myeloid neoplasms.
Wlodarski MW; Collin M; Horwitz MS
Semin Hematol; 2017 Apr; 54(2):81-86. PubMed ID: 28637621
[TBL] [Abstract][Full Text] [Related]
23. Transcription factor gene GATA2: Association of leukemia and nonsynonymous to the synonymous substitution rate across five mammals.
Mazumder TH; Uddin A; Chakraborty S
Genomics; 2016 Apr; 107(4):155-61. PubMed ID: 26850985
[TBL] [Abstract][Full Text] [Related]
24. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation.
Schwäble J; Choudhary C; Thiede C; Tickenbrock L; Sargin B; Steur C; Rehage M; Rudat A; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 Mar; 105(5):2107-14. PubMed ID: 15536149
[TBL] [Abstract][Full Text] [Related]
25. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice.
Nandakumar SK; Johnson K; Throm SL; Pestina TI; Neale G; Persons DA
Exp Hematol; 2015 Jul; 43(7):565-77.e1-10. PubMed ID: 25907033
[TBL] [Abstract][Full Text] [Related]
26. GATA2 regulates dendritic cell differentiation.
Onodera K; Fujiwara T; Onishi Y; Itoh-Nakadai A; Okitsu Y; Fukuhara N; Ishizawa K; Shimizu R; Yamamoto M; Harigae H
Blood; 2016 Jul; 128(4):508-18. PubMed ID: 27259979
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and molecular characteristics of GATA2 related pediatric primary myelodysplastic syndrome].
An WB; Liu C; Wan Y; Chen XY; Guo Y; Chen XJ; Yang WY; Chen YM; Zhang YC; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):477-483. PubMed ID: 31340620
[No Abstract] [Full Text] [Related]
28. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome).
Ostergaard P; Simpson MA; Connell FC; Steward CG; Brice G; Woollard WJ; Dafou D; Kilo T; Smithson S; Lunt P; Murday VA; Hodgson S; Keenan R; Pilz DT; Martinez-Corral I; Makinen T; Mortimer PS; Jeffery S; Trembath RC; Mansour S
Nat Genet; 2011 Sep; 43(10):929-31. PubMed ID: 21892158
[TBL] [Abstract][Full Text] [Related]
29. GATA2 is required for lymphatic vessel valve development and maintenance.
Kazenwadel J; Betterman KL; Chong CE; Stokes PH; Lee YK; Secker GA; Agalarov Y; Demir CS; Lawrence DM; Sutton DL; Tabruyn SP; Miura N; Salminen M; Petrova TV; Matthews JM; Hahn CN; Scott HS; Harvey NL
J Clin Invest; 2015 Aug; 125(8):2979-94. PubMed ID: 26214525
[TBL] [Abstract][Full Text] [Related]
30. AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
Melnick A; Carlile GW; McConnell MJ; Polinger A; Hiebert SW; Licht JD
Blood; 2000 Dec; 96(12):3939-47. PubMed ID: 11090081
[TBL] [Abstract][Full Text] [Related]
31. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
32. Acetylation of lysine 564 adjacent to the C-terminal binding protein-binding motif in EVI1 is crucial for transcriptional activation of GATA2.
Shimahara A; Yamakawa N; Nishikata I; Morishita K
J Biol Chem; 2010 May; 285(22):16967-77. PubMed ID: 20363750
[TBL] [Abstract][Full Text] [Related]
33. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations.
Hofmann I; Avagyan S; Stetson A; Guo D; Al-Sayegh H; London WB; Lehmann L
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1124-1130. PubMed ID: 32088370
[TBL] [Abstract][Full Text] [Related]
35. GATA2 gene analysis in several forms of hematological malignancies including familial aggregations.
Hamadou WS; Mani R; Besbes S; Bourdon V; Youssef YB; Eisinger F; Mari V; Gesta P; Dreyfus H; Bonadona V; Dugast C; Zattara H; Faivre L; Noguchi T; Khélif A; Sobol H; Soua Z
Ann Hematol; 2017 Oct; 96(10):1635-1639. PubMed ID: 28752392
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.
Theis F; Corbacioglu A; Gaidzik VI; Paschka P; Weber D; Bullinger L; Heuser M; Ganser A; Thol F; Schlegelberger B; Göhring G; Köhne CH; Germing U; Brossart P; Horst HA; Haase D; Götze K; Ringhoffer M; Fiedler W; Nachbaur D; Kindler T; Held G; Lübbert M; Wattad M; Salih HR; Krauter J; Döhner H; Schlenk RF; Döhner K
Leukemia; 2016 Nov; 30(11):2248-2250. PubMed ID: 27375010
[No Abstract] [Full Text] [Related]
37. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression.
Kumano K; Chiba S; Shimizu K; Yamagata T; Hosoya N; Saito T; Takahashi T; Hamada Y; Hirai H
Blood; 2001 Dec; 98(12):3283-9. PubMed ID: 11719365
[TBL] [Abstract][Full Text] [Related]
38. Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.
West RR; Hsu AP; Holland SM; Cuellar-Rodriguez J; Hickstein DD
Haematologica; 2014 Feb; 99(2):276-81. PubMed ID: 24077845
[TBL] [Abstract][Full Text] [Related]
39. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
40. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia.
Dong F; Brynes RK; Tidow N; Welte K; Löwenberg B; Touw IP
N Engl J Med; 1995 Aug; 333(8):487-93. PubMed ID: 7542747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
